ISDA

Deposition Date 2021-11-27

Release Date 2022-12-14

Last Version Date 2024-05-01

Entry Detail

PDB ID:

7QDL

Keywords:

TRANSCRIPTION

Title:

N-TERMINAL BROMODOMAIN OF HUMAN BRD4 with I-BET567

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli BL21(DE3)

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.67 Å

R-Value Free:

0.21

R-Value Work:

0.16

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Bromodomain-containing protein 4
Gene (Uniprot):BRD4
Chain IDs:A (auth: AAA)
Chain Length:127
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:O60885 Pfam ID:PF00439

Primary Citation

Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate.

Humphreys, P.G, Atkinson, S.J, Bamborough, P, Bit, R.A, Chung, C.W, Craggs, P.D, Cutler, L, Davis, R, Ferrie, A, Gong, G, Gordon, L.J, Gray, M, Harrison, L.A, Hayhow, T.G, Haynes, A, Henley, N, Hirst, D.J, Holyer, I.D, Lindon, M.J, Lovatt, C, Lugo, D, McCleary, S, Molnar, J, Osmani, Q, Patten, C, Preston, A, Rioja, I, Seal, J.T, Smithers, N, Sun, F, Tang, D, Taylor, S, Theodoulou, N.H, Thomas, C, Watson, R.J, Wellaway, C.R, Zhu, L, Tomkinson, N.C.O, Prinjha, R.K.Show

J.Med.Chem. 65 2262 2287 (2022)

PMID: 34995458 DOI: 10.1021/acs.jmedchem.1c01747

Abstact

Through regulation of the epigenome, the bromodomain and extra terminal (BET) family of proteins represent important therapeutic targets for the treatment of human disease. Through mimicking the endogenous N-acetyl-lysine group and disrupting the protein-protein interaction between histone tails and the bromodomain, several small molecule pan-BET inhibitors have progressed to oncology clinical trials. This work describes the medicinal chemistry strategy and execution to deliver an orally bioavailable tetrahydroquinoline (THQ) pan-BET candidate. Critical to the success of this endeavor was a potency agnostic analysis of a data set of 1999 THQ BET inhibitors within the GSK collection which enabled identification of appropriate lipophilicity space to deliver compounds with a higher probability of desired oral candidate quality properties. SAR knowledge was leveraged via Free-Wilson analysis within this design space to identify a small group of targets which ultimately delivered I-BET567 (27), a pan-BET candidate inhibitor that demonstrated efficacy in mouse models of oncology and inflammation.

Legend

Protein

Chemical

Disease

Primary Citation of related structures